Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sophia Airhart

Advanced Heart Failure and Transplant Cardiology Springfield, MA Medical Doctor

NPI 1427379825 CMS profile 1087192

3300 Main Street, 2Nd Fl, Suite A, Springfield, MA 01107

Open in the dashboard

General payments

$110,403

288 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$965,712 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Sophia Airhart of Springfield, MA is reported in the CMS Open Payments database as having received $110,403 across 288 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $965,712 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,408 26
2024 General $7,757 33
2023 General $25,491 67
2022 General $18,474 37
2021 General $17,194 36
2020 General $4,528 17
2019 General $26,551 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sophia Airhart
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Sophia Airhart were reported at $10,408. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Sophia Airhart Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $26,551 $863 $224–$4,562 $163
2020 $4,528 $452 $122–$3,992 $114
2021 $17,194 $550 $159–$3,571 $132
2022 $18,474 $729 $221–$4,357 $149
2023 $25,491 $1,002 $309–$5,827 $160
2024 $7,757 $931 $273–$5,204 $164
2025 $10,408 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. United Therapeutics Corporation $43,658 81 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $23,939 30 payments
  3. Novartis Pharmaceuticals Corporation $13,678 18 payments
  4. Abbott Laboratories $10,116 60 payments
  5. Actelion Pharmaceuticals US, Inc. $6,203 30 payments
  6. CVRx, Inc. $5,356 12 payments
  7. Merck Sharp & Dohme Corporation $4,201 8 payments
  8. Amgen Inc. $889 9 payments
  9. Abiomed $523 7 payments
  10. Medtronic, Inc. $444 3 payments
  11. Other $1,396 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,688 28 payments
  2. Consulting Fee $37,830 17 payments
  3. Food and Beverage $10,800 190 payments
  4. Travel and Lodging $8,991 46 payments
  5. Education $94 7 payments
Products named General payments · program years 2019–2025
  1. Adempas $23,889 28 payments
  2. ENTRESTO Cardiovascular $10,961 16 payments
  3. ORENITRAM Pah $6,133 15 payments
  4. UPTRAVI $5,766 22 payments
  5. OPSUMIT $5,526 21 payments
  6. Barostim Neo System $5,356 12 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $5,168 20 payments
  8. ORENITRAM Pulmonary Arterial Hypertension $3,922 6 payments
  9. HeartMate 3 Left Ventricular Assist Device $3,475 12 payments
  10. ENTRESTO Cardiology/Vascular Diseases $2,716 2 payments
  11. Other $8,412 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,430

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$5,781,577

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

52%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Winrevair Sotatercept-Csrk Brand 79 $1,287,871
Opsumit Macitentan Brand 79 $993,476
Uptravi Selexipag Brand 22 $609,659
Tyvaso Dpi Treprostinil Brand 26 $597,318
Adempas Riociguat Brand 43 $590,135
Vyndamax Tafamidis Brand 16 $362,131
Entresto Sacubitril/Valsartan Brand 380 $337,301
Vyndaqel Tafamidis Meglumine Brand 13 $290,320
Jardiance Empagliflozin Brand 237 $220,043
Farxiga Dapagliflozin Propanediol Brand 246 $201,209

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$38,976

Medicare's payments for the services billed

Medicare patients

202

Average age 75

Services billed

681

88 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 60%
Atrial fibrillation 60%
Chronic kidney disease 51%
Arthritis 44%
Diabetes 39%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORENITRAM
  • United Therapeutics Corporation $3,904
$3,904 — —
TYVASO
  • United Therapeutics Corporation $2,525
$2,525 26 —
WINREVAIR
  • Merck Sharp & Dohme Corporation $24
$24 79 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $23
$23 79 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $23
$23 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record